Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread

The main objective of this study is to determine whether neoadjuvant chemotherapy with Carboplatin and paclitaxel plus standard cisplatin-based chemoradiation with extended fields improves overall survival rates compared to standard therapy alone in women with cervical cancer with paraaortic lymph node involvement. Women in the experimental arm will receive neoadjuvant chemotherapy with carboplatin and paclitaxel every 21 days during 3 cycles followed by standard therapy with extended field external radiation therapy and concomitant chemotherapy. Women in the control arm will receive standard

Trial Details

NCT ID
NCT03534713
Phase
PHASE3
Sponsor
University Hospital, Toulouse
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • Carboplatin
  • Paclitaxel
  • Cisplatin
  • Radiotherapy
Locations (sample)
  • Bordeaux, France|44.84124,-0.58046
  • Clermont-Ferrand, France|45.77969,3.08682
  • Créteil, France|48.79266,2.46569
  • Marseille, France|43.29695,5.38107
  • Pierre-Bénite, France|45.70359,4.82424

Key Eligibility Criteria

  • Women with histologically proven invasive carcinoma of the uterine cervix and para aortic lymphadenopathy determined by either a positive positron …
  • Performance status Eastern Cooperative Oncology Group 0-2
  • Stage International Federation of Gynecology and Obstetrics IB1 to IVA at diagnosis with para-aortic lymph node involvement
  • Adenocarcinoma or squamous cell carcinoma or adenosquamous carcinoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →